IMMUNEONCO-B: Application for Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma
IMMUNEONCO-B has submitted an application for the Phase III clinical trial of IMM0306 to the National Medical Products Administration of China. IMM0306 is a bispecific molecule targeting CD47 and CD20, the first of its kind to enter clinical stages globally. The drug enhances the activity of macrophages and NK cells by inhibiting the CD47-SIRPα interaction, effectively eliminating malignant B cells, reducing toxicity, and improving therapeutic efficacy. The company holds global intellectual property and commercialization rights for IMM0306
According to the Zhitong Finance APP, IMMUNEONCO-B (01541) announced that the group has submitted an application for the Phase III clinical trial of IMM0306 to the Center for Drug Evaluation of the National Medical Products Administration of China.
IMM0306, independently developed by the group, is a bispecific molecule targeting Cluster of Differentiation 47 (CD47) and Cluster of Differentiation 20 (CD20), and is the world's first CD47 and CD20 dual-target bispecific molecule to enter the clinical stage. IMM0306 blocks the "don't eat me" signal by inhibiting the CD47-SIRPα interaction, enhances the Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and NK cells, and preferentially binds to CD20 rather than CD47 to effectively eliminate malignant B cells while minimizing toxicity, thereby improving therapeutic efficacy.
As of the date of this announcement, the group holds global intellectual property and commercialization rights for IMM0306
